At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 290 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Rheumatoid Arthritis. Completed, enrolled 290 participants across 30 sites in 3 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Brazil, China
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 16, 2014
Enrollment StartOct 1, 2014
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.7 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally